

IN THE CLAIMS:

Please cancel claims 47-73, without prejudice. The status of the claims will be as follows.

26. (Previously Entered) A method for cellular grafting in myocardial tissue of an animal, comprising forming a stable cellular graft of cardiomyocyte cells in myocardial tissue of an animal, wherein the engrafted cells are viable for at least six months.

27. (Previously Entered) A method for cellular grafting according to claim 26, which comprises the step of introducing embryonic cardiomyocyte cells into said myocardial tissue.

28. (Previously Entered) A method for cellular grafting according to claim 26, which comprises the step of introducing adult cardiomyocyte cells into said myocardial tissue.

29. (Previously Entered) A method for cellular grafting according to claim 27, wherein said myocardial tissue comprises diseased or damaged myocardial tissue and said cellular graft is for supplementing myocardial function.

30. (Previously Entered) A method for cellular grafting according to claim 29 wherein said myocardial tissue is infarcted myocardial tissue.

31. (Previously Entered) A method for cellular grafting according to claim 30, which comprises introducing embryonic cardiomyocyte cells into said infarcted myocardial tissue.

32. (Previously Entered) A method for cellular grafting according to claim 30, which comprises introducing adult cardiomyocyte cells into said infarcted myocardial tissue.
33. (Previously Entered) A method for cellular grafting according to claim 26, wherein said cardiomyocytes of said graft are non-immunogenic to said animal.
34. (Previously Entered) A method for cellular grafting according to claim 26 wherein said cardiomyocyte cells of said cellular graft are genetically identical to cells of said animal.
35. (Previously Entered) A method for cellular grafting according to claim 26 wherein said animal is a mammal.
36. (Previously Entered) A method for cellular grafting according to claim 26, wherein said cardiomyocyte cells of said graft are non-immortalized.
37. (Previously Entered) A method for cellular grafting according to claim 35 wherein said myocardial tissue is ventricular myocardial tissue.
38. (Previously Entered) A method for cellular grafting according to claim 37, wherein said ventricular myocardial tissue is left ventricular myocardial tissue.
39. (Previously Entered) A method for cellular grafting according to claim 26, wherein said cellular graft comprises cardiomyocyte cells intercellularly coupled to cardiomyocyte cells of said myocardial issue by junctional complexes.

40. (Previously Entered) A method for cellular grafting according to claim 26, wherein the cellular graft comprises cardiomyocyte cells that carry a transgene encoding a recombinant molecule.

41. (Previously Entered) A method for cellular grafting according to claim 40, wherein the recombinant molecule is a protein.

42. (Previously Entered) A method for cellular grafting according to claim 41, wherein the protein is delivered to said myocardial tissue by the graft cardiomyocyte cells.

43. (Previously Entered) A method for cellular grafting according to claim 42 wherein the protein is an angiogenic factor or neurotrophic agent.

44. (Previously Entered) A method for cellular grafting according to claim 43 wherein the protein is an angiogenic factor that induces neovascularization in the myocardial tissue.

45. (Previously Entered) A method for cellular grafting according to claim 44, wherein the angiogenic factor is basic or acidic Fibroblast Growth Factor, Transforming Growth Factor-Beta, Vascular Endothelial Growth Factor, or Hepatocyte Growth Factor.

46. (Previously Entered) A method for cellular grafting according to claim 43, wherein the protein is a neurotrophic agent.

47-73. (Cancelled)